Carl DeSelm
Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carl DeSelm as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04331041 · Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaWashington University School of Medicine · active not recruiting · Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Harnessing TLR4 Signaling Pathways in CAR Dendritic Cells to Overcome Tumor Immune ToleranceR21CA313766 · NCI · WASHINGTON UNIVERSITY · fiscal years 2026 · $399,829 awarded in 2026Same name and institution; not confirmed by an ID
- Re-wiring PDAC Tumor Immunity Through Dendritic CellsR01CA262506 · NCI · WASHINGTON UNIVERSITY · fiscal years 2021 to 2025 · $473,084 awarded in 2025Same name and institution; not confirmed by an ID
- Immune Activating CAR-Modified Antigen Presenting CellsDP5OD026427 · OD · WASHINGTON UNIVERSITY · fiscal years 2018 to 2022 · $393,750 awarded in 2022Same name and institution; not confirmed by an ID
- The Role of Paxillin in the OsteoclastF30AG032795 · NIA · WASHINGTON UNIVERSITY · fiscal years 2009 to 2011 · $46,800 awarded in 2011Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor ImmunityR01CA248917 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, HYUN KIM, Julie Kristina Schwarz · fiscal years 2020 to 2024Named on NCT04331041
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:40 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed